TherapeuticsMD (TXMD) Common Equity (2010 - 2026)

TherapeuticsMD (TXMD) has reported Common Equity for 17 consecutive years, with $27.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 0.59% year-over-year to $27.1 million; the trailing twelve-month figure through Jun 2026 stood at $27.1 million (down 0.59% YoY), and the FY2025 full-year result was $26.9 million, down 1.8% from the prior year.
• Common Equity improved to $27.1 million in Q2 2026 per TXMD's latest filing, from $27.0 million in the prior quarter.
• Across five years, Common Equity topped out at $35.1 million in Q4 2022 and bottomed at -$140.6 million in Q1 2022.
• Historically, Common Equity has averaged $11.9 million across 5 years, with a median of $27.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity plunged 1383.22% in 2022, then jumped 222.77% in 2023.
• Over 5 years, Common Equity stood at $35.1 million in 2022, then slipped by 16.66% to $29.3 million in 2023, then slipped by 6.55% to $27.4 million in 2024, then dropped by 1.8% to $26.9 million in 2025, then rose by 0.95% to $27.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $27.1 million, $27.0 million, and $26.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.